poisar

Stocks · News reference

Gubra CEO Sees Potential for GUB-UCN2 in Multiple Indications

Fiscal.ai

Gubra's CEO has highlighted the potential for the company's drug candidate GUB-UCN2 to be applied across several different medical indications.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading